ACHE and Alzheimer disease: The in silico molecular docking study of Abd El-Aziz and colleagues demonstrating the EA anti-acetylcholinesterase activity in AD treatment [30] and the in vivo study of Harakeh and colleagues with EA-loaded nanoparticles in an AD rat model [33] bring evidence to the possible effect of EA on AD management, as well in protection against diabetes-associated behavioural deficits in rats [21], shown in Figure 4.